Shared on04 Sep 25
With key metrics such as future P/E (16.49x) and net profit margin (54.67%) remaining stable, Camurus’s fair value assessment is unchanged, with the consensus analyst price target holding steady at SEK832.17. What's in the News Camurus received UK MHRA marketing authorization for Oczyesa® (octreotide subcutaneous depot) for maintenance treatment of adult acromegaly patients, following comprehensive clinical studies including two Phase 3 trials.
Shared on23 Apr 25Fair value Increased 2.43%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 9.01%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 4.73%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 4.52%
AnalystConsensusTarget has increased profit margin from 32.7% to 48.9%, decreased future PE multiple from 29.2x to 17.9x and decreased shares outstanding growth rate from 0.0% to 0.0%.
Shared on12 Mar 25Fair value Decreased 4.80%
AnalystConsensusTarget has decreased profit margin from 66.1% to 32.7% and increased future PE multiple from 14.4x to 29.2x.